Cryptolepine, a naturally occurring indoloquinoline alkaloid used as an antimalarial drug in Central and Western Africa, has been found to bind to DNA in a formerly unknown intercalation mode. Evidence from competition dialysis assays demonstrates that cryptolepine is able to bind CG-rich sequences containing nonalternating CC sites. Here we show that cryptolepine interacts with the CC sites of the DNA fragment d(CCTAGG) 2 in a base-stacking intercalation mode. This is the first DNA intercalator complex, from ∼90 solved by X-ray crystallography, to bind a nonalternating (pyrimidine-pyrimidine) DNA sequence. The asymmetry of the drug induces a perfect stacking with the asymmetric site, allowing for the stability of the complex in the absence of hydrogen bonding interactions. The crystal structure of this antimalarial drug-DNA complex provides evidence for the first nonalternating intercalation and, as such, provides a basis for the design of new anticancer or antimalarial drugs.
Cryptolepine, a naturally occurring indoloquinoline alkaloid used as an antimalarial drug in Central and Western Africa, has been found to bind to DNA in a formerly unknown intercalation mode. Evidence from competition dialysis assays demonstrates that cryptolepine is able to bind CG-rich sequences containing nonalternating CC sites. Here we show that cryptolepine interacts with the CC sites of the DNA fragment d(CCTAGG) 2 in a base-stacking intercalation mode. This is the first DNA intercalator complex, from ∼90 solved by X-ray crystallography, to bind a nonalternating (pyrimidine-pyrimidine) DNA sequence. The asymmetry of the drug induces a perfect stacking with the asymmetric site, allowing for the stability of the complex in the absence of hydrogen bonding interactions. The crystal structure of this antimalarial drug-DNA complex provides evidence for the first nonalternating intercalation and, as such, provides a basis for the design of new anticancer or antimalarial drugs.
Malaria, by far the most important tropical parasite, causes an estimated annual 2.7 million deaths among the 300-500 million people suffering from the disease per year. Africa accounts for over 90% of reported cases, with an annual 20% increase of malaria-related illness and death. Malaria is responsible for as many deaths per annum as AIDS for all of the last 15 years. Drug resistance to malaria has become one of the most significant threats to human health and the search for new effective drugs is urgent. Although the mechanism of action of the antimalarial drugs is unclear, many of these drugs, such as chloroquine and quinacrine, are known to interact with DNA 1 .
Cryptolepine (5-methyl indolo[2,3b]-quinoline) is an indoloquinoline alkaloid first isolated from the roots of Cryptolepsis triangularis collected in Kisantu (Congo). Extracts of the roots of the related climbing liana Cryptolepsis sanguinolenta, in which cryptolepine is the main alkaloid, have been used clinically in Ghana for the treatment of malaria 2 , and also as a remedy against colic and stomach ulcers. Cryptolepine itself has been found to produce a variety of pharmacological effects, including hypotensive and antipyretic properties, presynaptic α-adrenoreceptor blocking action, antimuscarinic properties, antiinflammatory properties and antibacterial effects (for review see ref. 3) .
Cryptolepine has potent in vitro activity against the malaria parasite (Plasmodium falciparum) and possesses cytotoxic activity, inhibiting DNA synthesis in B16 melanoma cells 3 . The alkaloid was found to bind tightly to DNA and behaved as a typical intercalating agent. The drug interacts preferentially with CGrich sequences and discriminates against homooligomeric runs of A and T. The study 3 also led to the discovery that cryptolepine is a potent topoisomerase II inhibitor and a promising antitumor agent. Cryptolepine stabilizes topoisomerase II-DNA covalent complexes and stimulates the cutting of DNA at a subset of preexisting topoisomerase II cleavage sites 3, 4 . In addition, evidence suggests that cryptolepine may inhibit the detoxification of heme produced by malaria parasites in red blood cells as a result of the digestion of hemoglobin, similarly to chloroquine and related 4-aminoquinoline antimalarials 5 . Although the antimalarial activity of cryptolepine may involve a chloroquine-like action, interactions with DNA may also contribute. This is supported by a fluorescence microscopy study, which suggests that 
DNA-drug interactions
Two main kinds of noncovalent DNA-drug interactions are known: base intercalation 7 and minor groove binding 8 . Minor groove binders that specifically target DNA have been thoroughly investigated by Dervan 9 using hairpin iminopyridines, which allow a proper recognition of DNA sequences. Intercalators are the group of compounds that bind between the bases of DNA, thereby interrupting transcription, replication and/or topoisomerase activities 10 . Although some intercalators have been used as anticancer drugs, others are carcinogens. Bisintercalators 11 , trisintercalators 12 , tetraintercalators 13 and octakis-intercalators 14 , containing the same repeating intercalator group, have been synthesized. Cryptolepine is the first intercalator that appears to prefer or tolerate nonalternating steps (pyrimidinepyrimidine). Two main kinds of DNA-drug intercalation are observed. The first is perpendicular intercalation, typified by doxorubicin and daunomycin 7 , in which long fused-ring molecules penetrate perpendicularly to the base pair hydrogen bonds. Parallel basestacking intercalators, such as actinomycin 15 and acridine-type drugs 16 , which intercalate parallel to the base pair hydrogen bonds and stack their aromatic rings into the DNA bases ( Fig. 1) , exemplify the other type of intercalation. Perpendicular intercalators mainly go to CG and other alternating pyrimidine-purine sites, such as TG or CA. Parallel base-stacking intercalators can also go to nonalternating sequences. At present there are ∼90 structures of nucleic acid-intercalator complexes in the Nucleic Acid Database 17 that have been shown to have alternating-base intercalation sites, most being CG, a few GC and some TG.
The NMR structure of two intercalators, esperamicin A 1 18 and calicheamicin γ 1 19 , in complex with DNA indicate that they intercalate a single aromatic ring at a CC site. However, the small size of the intercalator and its two minor groove binding groups suggest that the sequence specificity of the drug is favored by the complementarity of the fit between the drug and the floor of the minor groove. These are minor groove binders, placing a sixmember aromatic ring between CC. The specificity is through the minor groove and not through the intercalation. The crystal structure reported here shows, for the first time, how cryptolepine interacts with the site d(CpC)-d(GpG) in a base-stacking intercalation mode.
Cryptolepine binding to DNA in solution
The Ren and Chaires competition dialysis method 20 was used to determine the sequence selectivity of cryptolepine for different small DNA fragments. In order to determine the preference of the ligand for base sequences of alternating and nonalternating C-G (CC and CG, respectively), and alternating and nonalternating A-T (AA and AT, respectively) base pairs, fragments of the same size were selected. This ensured that the same number of possible similar sites were available for ease of comparability.
The competition dialysis assay results indicated that cryptolepine prefers to bind to C-G rich sequences of DNA, with a tendency for nonalternating CC (Fig. 2) . The small differences between AA and AT are probably not significant. Comparison of the binding affinity of cryptolepine with those of the ligands used in the original Ren and Chaires experiment indicates that the binding affinity of cryptolepine is similar to that of other intercalators, such as actinomycin D, daunomycin, porphyrin compounds and chromomycin 20 . Previous footprinting analyses 3, 4 showed that tracts containing CC-GG, as well as several CG-GC sites were protected from DNase I cleavage, which is consistent with our binding data (Fig. 2) .
Complex structure
The complex d(CCTAGG)-cryptolepine has been crystallized, and its structure solved and refined to 1.4 Å resolution (Table 1 ; Fig. 2c ). The main feature of this structure is the perfect fit of the drug sandwiched between two consecutive C-G base pairs forming the first nonalternating site (CC)-(GG)-cryptolepine (Figs 1,3) . The aromatic six-membered ring of the cryptolepine molecule stacks between the two cytosines, whereas the fused aromatic, double six-membered ring portion of the molecule stacks between two guanines (Fig. 3d) . The five-membered ring, placed in the middle, gives asymmetry to the cryptolepine molecule and separates both aromatic groups. The positively charged N16 atom (quinoline group) between the two O6 atoms of consecutive guanines in the major groove of DNA and the N8 (indole nitrogen) between the O2 atoms of adjacent cytosines in the minor groove both enhance the stability of the complex (Fig. 3c) . This positively charged N16 nitrogen placed in the major groove between oxygens is also observed in the structure of the complex of 9-amino-DACA interacting with d(CGTACG) in the CG-drug site 16 . In this case, the charged nitrogen is placed between two oxygens from guanines in different strands; however, the charged nitrogen in the present structure is placed between oxygens of adjacent guanines of the same strand. The cryptolepine molecule is slightly bent, with a 6.8°angle between the two aromatic rings, which is similar to the 4.8°angle found in the high resolution X-ray structure of the cryptolepine tetraphenyl borate 21 . The presence of the five-membered ring positioned between the two aromatic groups allows this bend.
Neocryptolepine, an isomer of cryptolepine found to a lesser extent than cryptolepine in the plant extracts, shows a reduced affinity for DNA 22 . In this isomer, the charged group N16-C18H 3 of the quinoline moiety is interchanged with the C6 from the indole (Fig. 1) , with both nitrogens on the same side of the molecule. This reduced DNA affinity can be understood in terms of the reduced stability of the molecule within the complex. In the neocryptolepine molecule, the perfect fit that exists in the cryptolepine complex on both sides of the DNA in the major and minor grooves, where the nitrogen atoms are placed between oxygens (Fig. 3c) , is impossible because both nitrogen atoms are on the same side. The cryptolepine molecule has no hydrogenbonding contacts either with bases of the hexanucleotide or with solvent. The absence of such interactions suggests that stacking forces alone provide the stabilizing mechanism of the complex. The stacking interactions between the intercalated ligand and the DNA bases (Fig. 3d) show that the cryptolepine is aligned with its major axis parallel to the Watson and Crick hydrogen bonds of the base pairs. The positively charged cryptolepine chromophore is nearly enveloped by the two base pairs at the intercalation site and penetrates deeply into the helical stack, forming strong hydrophobic interactions with the base pairs and positioning its center of mass as close to the helix axis as possible, where the negative electrostatic potential of the DNA is the greatest 23 . In this way, the chromophore comes to lie in a position where both its hydrophobic and electrostatic interactions are maximized.
The analysis of solved DNA-drug complexes reveals the importance of stacking forces. Calorimetric and spectroscopic studies of the compound Hoechst 33258 in complex with d(CGCAAATTTGCG) 2 shows that hydrogen bonds contribute little to the stability of the complex compared to hydrophobic forces 24 .
Crystal packing
The asymmetric unit contains one strand of DNA hexamer, one intercalated cryptolepine molecule, 37 ordered water molecules and an additional cryptolepine molecule located on the two-fold axis, sandwiched between the two DNA hexamers. The crystallographic two-fold axis is coincident with the large axis of the drug molecule. This additional drug molecule links contiguous DNA hexamers in the crystal to form a continuous column of duplexes. Because the end-stacked ligand lies on a two-fold axis coincident with its major axis, the polarity of the DNA backbone reverses at this point, bringing the 5′ termini of adjacent helices into close juxtaposition, and the cytosine C1 oppose each other across the stacked ligand (Fig. 3b) . These DNA columns are perpendicular to the c-axis and rotated with respect to the neighbors, introducing the phosphate backbone in the minor groove of the neighboring DNA column.
DNA conformation
The DNA in the complex has a B-like conformation, with Watson-Crick base pairing. However, in accommodating the intercalated cryptolepine molecule, the DNA assumes conformational parameters significantly different from average B-DNA values. Nevertheless, the DNA structure is similar to other DNA complexes with base stacking intercalators, such as proflavine 25 and 9-amino-DACA 16 . In the intercalation cavity, the bases are separated by 7 Å, which is much larger than the 5-6 Å observed in the case of anthracycline drugs daunomycin and doxorubicin. In these cases, the drug intercalates perpendicular to the hydrogen bonds of the base pairs, causing a buckle on base pairs of the DNA site (Fig. 1) . In the present case, the major axis of the drug aligns parallel to the major axis of the base pairs to maximally occupy the intercalation site. To achieve this major opening of the bases, the sugar-phosphate backbone makes a coupled rotation of the α/γ main torsion angles at cytosine C2, bringing the oxygen O2P into the major groove. On the opposite chain, the same opening is achieved at guanine G6 by small variations in all the torsion angles. The DNA puckering is generally C2′-endo, except for the first cytidine, which is C3′-endo. At the intercalation sites, the sugars of cytidine C1 and C2 adopt the conformation C3′-endo and C2′-endo, a configuration frequently found in intercalator-dinucleotide monophosphate complexes 16 . DNA helical twist at the intercalation site is 24°, being unwound by 12°F 
Conclusions
The perpendicular intercalators (daunomycin and doxorubicin) prefer alternating sites (CG), which allow them to be located at the center of mass of the DNA. In contrast, the parallel basestacking drugs may adapt more readily to the nonalternating sites (CC), leading to better stacking interaction. In addition, the asymmetry of the drug enhances its fitting with the target in the case of nonalternating sites (CC)-(GG) because it allows a different stacking on one side (CC) or the other (GG) (Fig. 1) .
Methods
Ren and Chaires competition dialysis experiment for cryptolepine. Different DNA fragments were dialyzed against a common ligand solution, and their total concentration within each dialysis bag was determined spectrophotometrically. The extinction coefficients for the DNA fragments used in the experiment were obtained by the Boser approach 26 and was found to be 28,600 M -1 cm -1 at 369 nm for cryptolepine 3 . In the assay, the same procedures and solutions were used as described in the original experiment 20 . A buffer consisting of 6 mM Na 2 HPO 4 , 2 mM NaH 2 PO 4 , 1 mM NaEDTA and 185 mM NaCl, pH 7.0, was used. In this buffer, all DNA fragments, including d(CGCGCGCG), should be in the B-DNA form. In the experiment, 0.5 ml Spectro/Por DispoDialyzer units with membrane pores of 2,000 Da were used. A second experiment using a membrane pore size of 1,000 Da was performed with similar results. The values shown are for both experiments (mean ± standard deviation). During the experiment, all the DNA fragments are in equilibrium with the same free ligand concentration so that the amount of cryptolepine bound to each fragment is proportional to the association constant for ligand binding.
Crystal structure resolution. Crystals were grown by mixing 0.5 µl of 5 mM cryptolepine hydrochloride and 0.5 µl of 3 mM d(CCTAGG) with 1.0 µl of the crystalization solution containing 5 mM magnesium acetate, 25 mM 2-(N-morpholino)propanesulfonic acid (MES), pH 6.5, and 1.25 M ammonium sulfate. Single crystals were flash-frozen in a stream of evaporating liquid nitrogen at 120 K. Diffraction data were collected at EMBL beamline BW7A (DESY, Hamburg). The structure was solved by molecular replacement using DNA coordinates of the d(CGTACG)-9-amino-DACA structure, without the drug as starting model, with AMoRe 27 . Refinement followed with CNS 28 , first as a rigid body. The optimum orientation of the intercalated cryptolepine was identified by placing the drug at each of the four possible positions, and refining until the best fit and corresponding best R-factor (28.2%) and R free (33.2%) were found. At this stage, an iterative refinement procedure was carried out using SHELX-97 (ref. 29) , interspersed with inspection of electron density maps, water positioning and manual model rebuilding with TURBO-FRODO 30 . For cryptolepine, bond lengths and bond angles were refined to specified target values obtained from the cryptolepine structure determined by Wright et al. 21 The DNA bases and the two fused ring system of the cryptolepine were restrained to planar, whereas all other torsion angles remained unrestrained. No hydrogen bond restraints were used (Table 1) .
Coordinates. The coordinates have been deposited in the Protein Data Bank (accession code 1K9G). 
